Status:
COMPLETED
Effect of Quercetin on Prophylaxis and Treatment of COVID-19
Lead Sponsor:
Kanuni Sultan Suleyman Training and Research Hospital
Collaborating Sponsors:
Orbiteratec (funding)
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. The investigators hypothesize that querc...
Detailed Description
Novel Coronavirus is defined to be the cause of COVID-19, recently. It's known that COVID-19 goes with excessive immune reaction of human body in severe cases. Quercetin is reported to be effective on...
Eligibility Criteria
Inclusion
- moderate-high risk for COVID-19
- obtained informed consent
Exclusion
- declined to participate
- genetic/chromosomal abnormalities
- any kind of sensitivity or allergy for quercetin
- history of previous hypersensitivity with quercetin
Key Trial Info
Start Date :
March 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2020
Estimated Enrollment :
447 Patients enrolled
Trial Details
Trial ID
NCT04377789
Start Date
March 20 2020
End Date
August 31 2020
Last Update
February 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul, Turkey (Türkiye), 34303